Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
16.83
+4.48 (36.28%)
At close: Mar 5, 2026, 4:00 PM EST
16.60
-0.23 (-1.37%)
Pre-market: Mar 6, 2026, 9:11 AM EST
Tango Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Tango Therapeutics stock have an average target of 17.5, with a low estimate of 12 and a high estimate of 27. The average target predicts an increase of 3.98% from the current stock price of 16.83.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tango Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 1 | 2 | 3 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 8 | 7 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $15 → $19 | Buy | Maintains | $15 → $19 | +12.89% | Mar 6, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $18 → $20 | Strong Buy | Maintains | $18 → $20 | +18.84% | Mar 6, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $13 → $27 | Strong Buy | Maintains | $13 → $27 | +60.43% | Mar 6, 2026 |
| Mizuho | Mizuho | Buy Initiates $19 | Buy | Initiates | $19 | +12.89% | Feb 23, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $12 → $18 | Strong Buy | Maintains | $12 → $18 | +6.95% | Feb 6, 2026 |
Financial Forecast
Revenue This Year
11.46M
from 62.38M
Decreased by -81.64%
Revenue Next Year
13.04M
from 11.46M
Increased by 13.81%
EPS This Year
-1.28
from -0.87
EPS Next Year
-1.43
from -1.28
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 70.8M | 47.6M | |||
| Avg | 11.5M | 13.0M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 13.4% | 315.1% | |||
| Avg | -81.6% | 13.8% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.18 | -1.04 | |||
| Avg | -1.28 | -1.43 | |||
| Low | -1.49 | -1.77 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.